虹膜睫状体压后术治疗新生血管性青光眼

目的 :评价虹膜睫状体压后术治疗新生血管性青光眼的效果。方法 :对 2 8例 (2 8眼 )新生血管性青光眼采用虹膜睫状体压后术治疗。术后随访 10～ 60个月 ,平均 46 2月。结果 :术后眼压控制在 0 798kPa～ 2 793kPa 2 2眼 ,其中 4眼需加用一种降眼压药物 ;成功率为 78 5 7% ;另 4眼眼压 <0 798kPa ,2眼眼压 >2 793kPa ,术后早期并发症有短暂性前房积血及葡萄膜炎等 ;远期并发症少数白内障加速发展。结论 :虹膜睫状体压后术治疗新生血管性青光眼方法简单 ,远期效果较好     

新生血管性青光眼的治疗动态

新生血管性青光眼是临床常见的难治性眼病,其治疗主要包括原发疾病的治疗和降眼压治疗.原发病包括糖尿病性视网膜病变、缺血型视网膜中央静脉阻塞和眼部缺血综合征等.近年来,抗血管内皮生长因子类药物(如Bevacizumab)、多点扫描激光光凝、小梁切除术联合丝裂霉素C、青光眼引流装置、玻璃体切除手术和光动力疗法的应用使新生血管性青光眼的治疗方式有了诸多选择,并取得了较好的效果.本文对新生血管性青光眼的治疗进展进行综述.     

Goniophotocoagulation for neovascular glaucoma

A new treatment, goniophotocoagulation, for neovascularization of the anterior chamber angle has been applied with the argon laser to 21 eyes of 20 patients. Three of the eyes had neovascularization related to central retinal vein occlusion. In the other 18 eyes the neovascularization was related to diabetic retinopathy. A specific protocol has been followed since January 1973. The results so far indicate that closure of the angle and progression of the usual chain of pathologic events in neovascular glaucoma were prevented in 10 (77%) of the 13 eyes having an average follow-up of 22 months. We believe that goniophotocoagulation of the angle deserves more extensive, judicious, and carefully monitored clinical use. Our results suggest that this new technique is safe and reasonably effective in preventing progressive neovascularization of the angle, synechial closure, and severe nonvascular glaucoma.     

Ahmed青光眼阀植入术治疗新生血管性青光眼

目的:探讨Ahmed青光眼引流阀植入术治疗新生血管性青光眼的疗效及其并发症的防治。方法:回顾性分析18例18眼新生血管性青光眼行Ahmed青光眼阀植入术的疗效,主要观察指标为手术前后视力、眼压、并发症及手术成功率等,术后随访6~18mo。结果:术后最佳矫正视力不变11眼,提高5眼,下降2眼。术后眼压控制的有效率达到89%,术后并发症主要是早期的短暂性浅前房和高眼压、前房积血以及晚期的滤过道瘢痕纤维化。结论:Ahmed引流阀植入术是治疗新生血管性青光眼的一种比较有效的方法。     

新生血管性青光眼联合手术治疗疗效观察

目的 探讨联合手术治疗新生血管性青光眼的疗效.方法 对3l例(31只眼)新生血管性青光眼患者采用联合手术治疗方法:标准小梁切除术,应用丝裂霉素C,羊膜植入,全视网膜冷凝术.结果 术后5～7 d眼压7～18 mmHg(平均12.5 mmHg),术后3个月(31只眼)眼压10～29 mmHg(平均13.5 mmHg),术后6个月(28只眼)眼压10～31 mmHg(平均17.5 mmHg),术后12个月(24只眼)眼压11-31mml-1g(平均17 mmHg);术后3个月(31只眼)眼压低于21mmHg为完全成功有25只眼,条件成功有4只眼,成功率93.5%;术后6个月(28只眼)完全成功有19只眼,条件成功有5只眼,成功率85.7%;术后12个月(24只眼)眼压完全成功有12只眼,条件成功有7只眼,成功率79.1%.术后6个月(28只眼)有功能性滤过泡14只眼,非功能性滤过泡14只眼;术后12个月(24只眼)有功能性滤过泡11只眼,非功能性滤过泡13只眼.术后3月(31只眼)虹膜新生血管消失24只眼,术后12个月(24只眼)虹膜新生血管消失18只眼.手术后并发症:前房出血有11只眼;有3只眼前房渗出;有6只眼有脉络膜脱离;元前房消失,有1只眼恶性青光眼.结论 对新生血管性青光眼行联合手术:标准小梁切除术,应用丝裂霉素C,植入羊膜,全视网膜冷凝术效果肯定,并发症少,安全有效.     

Draining implant for neovascular glaucoma

We treated 12 eyes with advanced neovascular glaucoma with a modification of drainage implant surgery. All 12 eyes had rubeosis iridis and severe pain and nine had undergone previous glaucoma surgery. After follow-up periods of two to 24 months (mean, 11.3 months), nine of 12 eyes had intraocular pressures of less than 24 mm Hg (mean preoperative value, 49.5 +/- 8.2 mm Hg; mean postoperative value, 22.2 +/- 12.9 mm Hg). Surgery was unsuccessful in three eyes, in two because the anterior chamber remained flat postoperatively and in one because a large hyphema blocked the tube 15 months postoperatively. Our procedure, which uses a Y-shaped Teflon tube, is easy to perform, is well tolerated by the eye, and is associated with a low risk of serious complications.     

新生血管性青光眼联合手术治疗的临床观察

目的探讨联合手术治疗新生血管性青光眼（NVG）的疗效。方法对53例（53眼）NVG根据病情分3组采用联合手术的治疗方法。（1）A组23眼,先应用多波长氪激光行超广泛视网膜光凝术,光凝术后1～2周进行小梁切除术,术中应用丝裂霉素C（0．4mg／mL）棉片放置巩膜瓣下3～5rain。（2）B组17眼,先应用氪绿激光对虹膜面及房角新生血管直接光凝,2周后行小梁切除术,术中应用丝裂霉素c。（3）C组13眼,选用睫状体冷凝联合全周边视网膜冷凝术。结果6个月随访时：（1）A组成功率78．3％;平均眼压为（17．35±5．23）mmHg。（2）B组成功率为82．4％;平均眼压为（15．94±4．17）mmHg。（3）c组成功率为76．9％;平均眼压为（17．31±5．00）mmHg。结论针对不同程度的NVG要采用不同的治疗方法,并根据病情的发展随时调整治疗方案。     

Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report

PURPOSE: This study aimed to investigate the safety and efficacy of trabeculectomy with intraoperative mitomycin C (MMC) in the management of eyes with neovascular glaucoma (NVG). METHODS: Fifteen eyes of 14 patients with NVG were included in the study. NVG was secondary to central retinal vein occlusion (3 eyes), hemiretinal vein occlusion (2 eyes), proliferative diabetic retinopathy (8 eyes), branch retinal vein occlusion (1 eye) and idiopathic (1 eye). Preoperative retinal ablation was performed in eyes with evidence of posterior segment ischaemia. Following this, all eyes underwent trabeculectomy with intraoperative MMC (0.4 mg/ml for 3 minutes). Clinical outcome assessment included visual acuity, intraocular pressure (IOP), bleb appearance, identification of complications and antiglaucoma medications required to control IOP. RESULTS: The mean IOP decreased from 38.6 +/- 12.9 mmHg (range, 15-64 mmHg) to 17.4 +/- 9.33 mmHg (range, 4-34 mmHg) (P = 0.001). Preoperative visual acuity ranged from light perception to 6/9 in the affected eye. Thirteen (86.6%) of 15 eyes improved vision or retained preoperative vision, one (6.7%) eye lost light perception and one (6.7%) eye developed tractional retinal detachment two years after trabeculectomy. Ten (66.7%) of 15 eyes were classified as surgical success with a mean follow-up of 28.6 +/- 26.3 months (range, 2-82 months). None of the patients developed choroidal haemorrhage, hypotony maculopathy, late onset bleb leak or endophthalmitis. CONCLUSION: Trabeculectomy with intraoperative MMC is a good treatment modality in the management of eyes with NVG.     

Bevacizumab as adjuvant for neovascular glaucoma

Purpose: We aimed to evaluate the longterm effects of intraocular bevacizumab (Avastin^®) injections as adjuvant treatment in patients with neovascular glaucoma. Methods: Twenty eyes of 18 consecutive patients with secondary neovascular glaucoma caused by proliferative diabetic retinopathy (n = 7), ischaemic central retinal vein occlusion (n = 7), ischaemic ophthalmopathy (n = 2) and retinal ischaemia resulting from persistent detachment (n = 2) were treated with intraocular bevacizumab injections (1.25 mg/0.05 ml) in addition to other treatments. The main outcome measure was the change in degree of iris rubeosis. Secondary outcomes included intraocular pressure (IOP), best corrected visual acuity (BCVA) and numbers of additional interventions or antiglaucoma medications administered after injection. Results: Mean (± standard deviation) follow‐up was 67.7 ± 13.8 weeks (range 50–93 weeks). At the last follow‐up, complete regression of rubeosis was detectable in five (20%) eyes, incomplete regression in seven (35%), stabilization in six (30%), and an increase in two (10%) eyes. Mean IOP was 26.0 ± 8.9 mmHg at baseline and significantly decreased to 14.75 ± 5.3 mmHg at the last follow‐up visit (p = 0.000005). Mean baseline BCVA (logMAR [logarithm of the minimum angle of resolution] 1.43 ± 0.89) was stabilized during the follow‐up period (logMAR 1.5 ± 0.98). Patients received an average of 2.75 injections. Additional treatments were laser photocoagulation in 13 (65%) eyes, cyclodestructive procedure in 14 (70%), cryopexy in six (30%), drainage procedures in two (10%), and vitrectomy in five (25%) eyes. Conclusions: Bevacizumab may be beneficial as adjuvant treatment in neovascular glaucoma because of its anti‐angiogenic properties and its ability to prevent establishment or progression of angular obstruction. The causative disease inducing the angiogenic process requires treatment in all cases. Antiglaucoma treatment is needed in cases of persistent elevated IOP.     

减压阀引流术治疗新生血管性青光眼

为评价青光眼减压阀引流术治疗新生血管性青光眼,在视网膜血管性疾病、糖尿病、眼外伤所致的新生血管性青光眼２９例２９眼施行青光眼减压阀引流术,植入Ａｈｍｅｄ减压阀２０眼,Ｋｒｕｐｉｎ减压阀９眼。青光眼控制标准为６ｍｍＨｇ≤眼压≤２１ｍｍＨｇ,视功能保持或有所改善。结果：手术总成功率７５．８６％,眼压从术前平均５２．５６±１４．５１ｍｍＨｇ下降到２０．１５±１３．２６ｍｍＨｇ,平均随访１７．８３个月。有７眼在眼压正常后虹膜新生血管完全消退。术后３个月成功率７９．３１％,６个月成功率７６．１９％,１年成功率６６．６７％。主要手术并发症有前房导管口阻塞１３．７９％,浅前房１０．３４％,前房出血３．４５％。结论：青光眼减压阀引流术治疗新生血管性青光眼获得较为满意的疗效,是目前值得推荐的治疗选择。     

新生血管性青光眼的联合手术治疗观察

目的:探讨视网膜光凝或视网膜冷凝联合小梁切除术治疗新生血管性青光眼的疗效。方法:新生血管性青光眼64例64眼,首先行视网膜光凝或视网膜冷凝,再行小梁切除术,术后观察视力、眼压、虹膜新生血管、球结膜滤过泡及手术并发症等。结果:术后随访6～12mo,视力均无明显改善,平均眼压自术前47.89±6.74mmHg随访末降至18.41±2.16mmHg,控制在21mmHg以下者53眼(73%)。结论:视网膜光凝或视网膜冷凝联合小梁切除术治疗新生血管性青光眼有较好的长期疗效。     

Ahmed青光眼阀植入治疗新生血管性青光眼

目的探讨Ahmed青光眼阀植入治疗新生血管性青光眼的有效性和安全性。方法采用Ahmed青光眼阀治疗新生血管性青光眼32例(32眼)。为视网膜血管性疾病及糖尿病所致的新生血管性青光眼。疗效评价:术后眼压8~21 mmHg,视功能保持或有改善为治愈。术后平均随访14月。结果手术成功率为71.87%,眼压从术前(54.32±15.48)mmHg下降为术后(19.55±5.76)mmHg。主要并发症有:早期低眼压、前房延缓形成、前房导管口阻塞、前房积血。结论Ahmed青光眼阀治疗新生血管性青光眼是一种有效的手术方法。     

两阶段房水引流物植入术在新生血管性青光眼治疗中的应用

目的：探讨两阶段房水引流物植入手术在新生血管性青光眼治疗中的应用价值。方法：对１３例新生血管性青光眼患者行两阶段房水引流物植入手术,并根据不同的病因及眼压控制情况采取相应的改良技术和辅助治疗,病人追踪随访时间为６～１２个月。结果：所有病例术前眼压大于等于２３ｍｍＨｇ（３．０５ｋＰａ）,手术治疗后最后一次复查结果显示眼压控制在６～２１ｍｍＨｇ（０．７９８～２．７９３ｋＰａ）之间７例（约占５４％）,加用降眼压药后眼压控制在２１ｍｍＨｇ（２．７９３ｋＰａ）２例,总成功率近７０％。８例视力保持在术前水平或有所提高（占６２．３％）,５例由于原发病恶化及眼压控制不良,视力较术前下降（占３７．６％）。结论：两阶段房水引流物植入手术为新生血管性青光眼的治疗提供了新的选择